BioCentury | Sep 9, 2013
Finance

E round in the hand vs. IPO in the bush

...are up nearly 200% since its formation from the merger between Astex Therapeutics Ltd. and SuperGen Inc....
...tracked against Astex's daily share price below. Source: BCIQ: BioCentury Online Intelligence A. 7/20/11 - SuperGen Inc....
BioCentury | Sep 2, 2013
Clinical News

SGI-110: Phase I/II data

...elsewhere from Eisai. Celgene Corp. (NASDAQ:CELG, Summit, N.J.) markets Vidaza azacitidine for MDS. In 2011, SuperGen Inc....
BioCentury | Aug 29, 2013
Top Story

Astex up on data for second-generation Dacogen

...1 (DNMT1) inhibitor, is a second-generation version of Astex's MDS drug Dacogen decitabine. In 2011, SuperGen Inc....
BioCentury | Jul 1, 2013
Clinical News

SGI-110: Interim Phase I/II data

...elsewhere from Eisai. Celgene Corp. (NASDAQ:CELG, Summit, N.J.) markets Vidaza azacitidine for MDS. In 2011, SuperGen Inc....
BioCentury | Apr 15, 2013
Clinical News

Nipent pentostatin data

...patient group. Data were presented at the American Society of Hematology meeting in San Diego. SuperGen Inc....
BioCentury | Dec 3, 2012
Clinical News

PLX cells regulatory update

...compound for aplastic anemia for which the designation has not been withdrawn - etiocholanedione from SuperGen Inc....
BioCentury | Apr 23, 2012
Clinical News

SGI-110: Interim Phase I/II data

...Astex. Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) has rights elsewhere from Eisai. In 2011, SuperGen Inc....
BioCentury | Feb 13, 2012
Clinical News

Dacogen decitabine regulatory update

...EU for AML. Eisai markets the hypomethylating agent in North America under a license from SuperGen Inc....
BioCentury | Jan 23, 2012
Finance

Highlights of weekly biotech stock moves

...review of its internal pipeline and drug discovery programs following its merger last year with SuperGen Inc....
BioCentury | Jan 23, 2012
Company News

Astex Pharmaceuticals, GlaxoSmithKline deal

...GlaxoSmithKline to discover cancer therapeutics based on epigenetic targets. GSK originally entered the deal with SuperGen Inc....
Items per page:
1 - 10 of 511
BioCentury | Sep 9, 2013
Finance

E round in the hand vs. IPO in the bush

...are up nearly 200% since its formation from the merger between Astex Therapeutics Ltd. and SuperGen Inc....
...tracked against Astex's daily share price below. Source: BCIQ: BioCentury Online Intelligence A. 7/20/11 - SuperGen Inc....
BioCentury | Sep 2, 2013
Clinical News

SGI-110: Phase I/II data

...elsewhere from Eisai. Celgene Corp. (NASDAQ:CELG, Summit, N.J.) markets Vidaza azacitidine for MDS. In 2011, SuperGen Inc....
BioCentury | Aug 29, 2013
Top Story

Astex up on data for second-generation Dacogen

...1 (DNMT1) inhibitor, is a second-generation version of Astex's MDS drug Dacogen decitabine. In 2011, SuperGen Inc....
BioCentury | Jul 1, 2013
Clinical News

SGI-110: Interim Phase I/II data

...elsewhere from Eisai. Celgene Corp. (NASDAQ:CELG, Summit, N.J.) markets Vidaza azacitidine for MDS. In 2011, SuperGen Inc....
BioCentury | Apr 15, 2013
Clinical News

Nipent pentostatin data

...patient group. Data were presented at the American Society of Hematology meeting in San Diego. SuperGen Inc....
BioCentury | Dec 3, 2012
Clinical News

PLX cells regulatory update

...compound for aplastic anemia for which the designation has not been withdrawn - etiocholanedione from SuperGen Inc....
BioCentury | Apr 23, 2012
Clinical News

SGI-110: Interim Phase I/II data

...Astex. Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) has rights elsewhere from Eisai. In 2011, SuperGen Inc....
BioCentury | Feb 13, 2012
Clinical News

Dacogen decitabine regulatory update

...EU for AML. Eisai markets the hypomethylating agent in North America under a license from SuperGen Inc....
BioCentury | Jan 23, 2012
Finance

Highlights of weekly biotech stock moves

...review of its internal pipeline and drug discovery programs following its merger last year with SuperGen Inc....
BioCentury | Jan 23, 2012
Company News

Astex Pharmaceuticals, GlaxoSmithKline deal

...GlaxoSmithKline to discover cancer therapeutics based on epigenetic targets. GSK originally entered the deal with SuperGen Inc....
Items per page:
1 - 10 of 511